Long-term probability of detecting drug-resistant HIV in treatment-naive patients initiating combination antiretroviral therapy.
暂无分享,去创建一个
Delpech | B. Gazzard | C. Leen | D. Pillay | A. Winston | C. Sabin | P. Easterbrook | A. Phillips | M. Johnson | J. Ainsworth | M. Gompels | C. Orkin | A. Schwenk | A. Geretti | M. Zuckerman | E. Fearnhill | D. Dunn | K. Porter | E. Smit | A. Babiker | A. Cozzi-Lepri | J. Walsh | M. Fisher | R. Gilson | Jane Anderson | T. Hill | L. Bansi | S. Kaye | S. Burns | S. Cameron | T. Sadiq | N. Mackie | Uk Collaborative Grp Hiv Drug Resi | Uk Hyalgan Study Grp | Jane Anderson
[1] D. Richman,et al. Update of the drug resistance mutations in HIV-1: December 2009. , 2009, Topics in HIV medicine : a publication of the International AIDS Society, USA.
[2] D. Pillay,et al. Emergence of drug resistance in HIV type 1-infected patients after receipt of first-line highly active antiretroviral therapy: a systematic review of clinical trials. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[3] F. Vidal,et al. First-line antiretroviral therapy with efavirenz or lopinavir/ritonavir plus two nucleoside analogues: the SUSKA study, a non-randomized comparison from the VACH cohort. , 2008, The Journal of antimicrobial chemotherapy.
[4] Lynne Peeples,et al. Class-sparing regimens for initial treatment of HIV-1 infection. , 2008, The New England journal of medicine.
[5] J. Hammond,et al. Efficacy and Safety of Atazanavir, With or Without Ritonavir, as Part of Once-Daily Highly Active Antiretroviral Therapy Regimens in Antiretroviral-Naive Patients , 2008, Journal of acquired immune deficiency syndromes.
[6] A. Telenti,et al. Emergence of HIV-1 drug resistance in previously untreated patients initiating combination antiretroviral treatment: a comparison of different regimen types. , 2007, Archives of internal medicine.
[7] A. Cheng,et al. K65R development among subtype C HIV-1-infected patients in tenofovir DF clinical trials. , 2007, AIDS.
[8] B. Gazzard,et al. Tenofovir Disoproxil Fumarate, Emtricitabine, and Efavirenz Versus Fixed-Dose Zidovudine/Lamivudine and Efavirenz in Antiretroviral-Naive Patients: Virologic, Immunologic, and Morphologic Changes-A 96-Week Analysis , 2006, Journal of acquired immune deficiency syndromes.
[9] J. Bartlett,et al. Long-Term Results of Initial Therapy With Abacavir and Lamivudine Combined With Efavirenz, Amprenavir/Ritonavir, or Stavudine , 2006, Journal of acquired immune deficiency syndromes.
[10] D. Podzamczer,et al. A Once-Daily Lopinavir/Ritonavir-Based Regimen Provides Noninferior Antiviral Activity Compared With a Twice-Daily Regimen , 2006, Journal of acquired immune deficiency syndromes.
[11] C. Katlama,et al. The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial , 2006, The Lancet.
[12] R. Elston,et al. Long-term (120-Week) antiviral efficacy and tolerability of fosamprenavir/ritonavir once daily in therapy-naive patients with HIV-1 infection: an uncontrolled, open-label, single-arm follow-on study. , 2006, Clinical therapeutics.
[13] Joel E Gallant,et al. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. , 2006, The New England journal of medicine.
[14] Evan Wood,et al. Rates of antiretroviral resistance among HIV-infected patients with and without a history of injection drug use , 2005, AIDS.
[15] A. Antinori,et al. Lopinavir/Ritonavir or Efavirenz plus two Nucleoside Analogues as First-Line Antiretroviral Therapy: A Non-Randomized Comparison , 2005, Antiviral therapy.
[16] P. Cahn,et al. Abacavir Once or Twice Daily Combined With Once-Daily Lamivudine and Efavirenz for the Treatment of Antiretroviral-Naive HIV-Infected Adults: Results of the Ziagen Once Daily in Antiretroviral Combination Study , 2005, Journal of acquired immune deficiency syndromes.
[17] B. Gazzard,et al. Long term probability of detection of HIV-1 drug resistance after starting antiretroviral therapy in routine clinical practice , 2005, AIDS.
[18] P. Harrigan,et al. Predictors of HIV drug-resistance mutations in a large antiretroviral-naive cohort initiating triple antiretroviral therapy. , 2005, The Journal of infectious diseases.
[19] Steve A Castillo,et al. Abacavir versus zidovudine combined with lamivudine and efavirenz, for the treatment of antiretroviral-naive HIV-infected adults. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[20] C. Farthing,et al. Once-daily versus twice-daily lamivudine, in combination with zidovudine and efavirenz, for the treatment of antiretroviral-naive adults with HIV infection: a randomized equivalence trial. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[21] Edwin DeJesus,et al. SOLO: 48-week efficacy and safety comparison of once-daily fosamprenavir /ritonavir versus twice-daily nelfinavir in naive HIV-1-infected patients , 2004, AIDS.
[22] Joel E Gallant,et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. , 2004, JAMA.
[23] B. Gazzard,et al. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study , 2004, The Lancet.
[24] R. Elston,et al. GW433908/ritonavir once daily in antiretroviral therapy-naive HIV-infected patients: absence of protease resistance at 48 weeks , 2004, AIDS.
[25] Kholoud Porter,et al. The creation of a large UK‐based multicentre cohort of HIV‐infected individuals: The UK Collaborative HIV Cohort (UK CHIC) Study , 2004, HIV medicine.
[26] D. Podzamczer,et al. Genotype and phenotype at baseline and at failure in human immunodeficiency virus-infected antiretroviral-naive patients in a randomized trial comparing zidovudine and lamivudine plus nelfinavir or nevirapine. , 2003, The Journal of infectious diseases.
[27] G. Beall,et al. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. , 2002, The New England journal of medicine.
[28] D. Podzamczer,et al. A Randomized Clinical Trial Comparing Nelfinavir Or Nevirapine Associated to Zidovudine/Lamivudine in HIV-Infected Naive Patients (The Combine Study) , 2001, Antiviral therapy.
[29] A. Mocroft,et al. Participation in clinical studies among patients infected with HIV‐1 in a single treatment centre over 12 years , 2000, HIV medicine.
[30] D. Richman,et al. 2022 update of the drug resistance mutations in HIV-1. , 2022, Topics in antiviral medicine.
[31] P. Narciso,et al. EVALUATION OF DRUG RESISTANCE EMERGENCE IN HIV-1 INFECTED PATIENTS FAILING A FIRST-LINE HIGHLY ACTIVE ANTIRETROVIRAL THERAPY CONTAINING NNRTIS WITH OR WITHOUT THYMIDINE ANALOGUES , 2009 .
[32] A. Hsu,et al. Incidence of resistance in a double-blind study comparing lopinavir/ritonavir plus stavudine and lamivudine to nelfinavir plus stavudine and lamivudine. , 2004, The Journal of infectious diseases.